Tumour angiogenesis regulation by the miR-200 family.

  title={Tumour angiogenesis regulation by the miR-200 family.},
  author={Chad V Pecot and Rajesha Rupaimoole and Da Som Yang and Rehan Akbani and Cristina Ivan and Chunhua Lu and Sherry Yen-Yao Wu and H S Han and Maitri Y. Shah and Cristian Rodriguez-Aguayo and Justin N Bottsford-Miller and Yuexin Liu and Sang Bae Kim and Anna Unruh and Vianey Gonz{\'a}lez-Villasana and Li Huang and Behrouz Zand and Myrthala Moreno-Smith and Lingegowda Selanere Mangala and Morgan L Taylor and Heather J. Dalton and Vasudha Sehgal and Yunfei Wen and Yu Kang and Keith A. Baggerly and Ju-Seog Lee and Prahlad T. Ram and Murali K Ravoori and Vikas Kundra and Xinna Zhang and Rouba Ali-Fehmi and Ana-Maria Gonzalez-Angulo and Pierre P. Massion and George A. Calin and Gabriel L{\'o}pez-Berestein and Wei Zhang and Anil Sood},
  journal={Nature communications},
The miR-200 family is well known to inhibit the epithelial-mesenchymal transition, suggesting it may therapeutically inhibit metastatic biology. However, conflicting reports regarding the role of miR-200 in suppressing or promoting metastasis in different cancer types have left unanswered questions. Here we demonstrate a difference in clinical outcome based on miR-200's role in blocking tumour angiogenesis. We demonstrate that miR-200 inhibits angiogenesis through direct and indirect mechanisms… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 8 times over the past 90 days. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 131 extracted citations


Publications referenced by this paper.
Showing 1-10 of 43 references

a retrospective analysis of phase 2 and phase 3 trials

  • Tran, H. T. et al. Prognostic or predictive plasma cytokines, angiogenic factors for patients treated with pazopanib for me cancer
  • Lancet Oncol. 13, 827–837
  • 2012

Similar Papers

Loading similar papers…